Full-Time
Operations Manager
Updated on 9/10/2026
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Cary, NC, USA
In Person
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Cencora
See people who can refer or advise you
- A four-year bachelor's degree in business administration, accountancy, sales, marketing, computer science, human resources, or a similar vocation, or an equivalent combination of experience and education.
- At least 5 years of directly related and progressively responsible experience, including at least 2 years at a supervisory level.
- Professional manner and sense of urgency.
- Excellent interpersonal and communication skills.
- Strong organizational and time management skills.
- Exceptional work ethic and team leadership ability.
- Professional and approachable demeanor.
- Full understanding of cold chain management.
- Training, onboarding, and offboarding of associates.
- Environmental health and safety awareness.
- Security and access control awareness.
- Awareness of natural disaster response plans.
- HAZMAT certification or understanding of HAZMAT requirements.
- Recruit, hire, and retain talented human resources.
- Develop new employees and oversee staff training in handling procedures, including timely recurrent training to meet evolving business needs.
- Ensure compliance with all relevant standard operating procedures and good business practices.
- Develop local operational procedures and policies that ensure organizational quality.
- Review processes and workflows quarterly.
- Collaborate nationally and globally with other managers to develop business strategies, resolve issues, and support growth.
- Delegate responsibilities to ensure all shipments in transit through the station are properly managed.
- Monitor station activity, identify resource needs, manage station costs, and ensure quality objectives are maintained.
- Ensure critical cold chain requirements are met and qualify and maintain equipment supporting the business.
- Comply with Federal Aviation Administration, Transportation Security Administration, Food and Drug Administration, and other applicable regulations.
- Troubleshoot and manage problems, including agent relations, corrective and preventive action assessments, and root-cause analysis.
- Conduct performance reviews and evaluations to assess employee performance and identify professional development needs, including succession planning for direct reports.
- Conduct quarterly compensation reviews for direct reports.
- Foster a cooperative and harmonious workplace while maintaining high employee morale through team recognition and celebration of team achievements.
- Manage office expenses.
- Meet company reporting deadlines.
- Review key performance indicators.
- Maintain local vendor relationships and ensure quality standards by reviewing vendor, carrier, and agent contracts and driving rate negotiations and cost-saving opportunities.
- Understand and implement new technology to increase performance and productivity.
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Get referred to Cencora
See people who can refer or advise you
Simplify's Take
What believers are saying
- Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
- Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
- A $7 billion revolver and $1 billion buyback show lenders and management backing execution.
What critics are saying
- Opioid litigation still carries a $4.2 billion accrued liability through 2039.
- Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
- ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.
What makes Cencora unique
- Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
- Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
- Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Company News
Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.
Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.
Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.
Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.
Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.